Supplements
Supplement: GLAUKOS Istent Inject W Supplement 2022
![Supplement: GLAUKOS Istent Inject W Supplement 2022](/media/5gzhgbzp/glaukos-istent-inject-w-supplement-2022-banner.png?width=1640&height=500&v=1d896a8f7e6cd80)
Affecting an estimated 76 million people worldwide in 2020 (1), glaucoma is the leading cause of irreversible vision loss and the second leading cause of blindness worldwide (2). Open angle glau-coma (OAG) is the most common form, occurring in 74% of diagnosed glaucoma cases (3, 4). It is often seen in conjunction with cataract, with approximately one-in-five cataract patients also needing glaucoma medication (5). These numbers present both a daunting challenge and a major opportunity. Elevated intraocular pressure (IOP) remains the major risk factor for glaucoma, and most current treatments, including pharmacological, laser and surgical interventions, focus on lowering IOP (6). Yet each have drawbacks. Ocular hypotensive medications are reasonably safe and effective, but their pressure-reducing effects may wane over time, they can lead to ocular surface disease and conjunctival hyperemia, and adherence is notoriously problematic (7-11). Laser trabeculoplasty reliably reduces IOP but can lose effectiveness after three to five years (38-40) and some forms may induce inflammation in the intermediate term (12). And while incisional surgeries such as trabeculectomy and tube shunt implantation can reduce IOP dra-matically, they expose patients to safety risks, including endophthalmitis and hypotony, that can persist for the lifespan of treatment (13-15).
Tags: glaucoma
Latest Articles
Rule Number One: Protect the Eyes
Ophthalmologists hold a key role in athlete eye care for all ages and abilities.
Olympic Committee Targets Sports-Related Ophthalmic Issues
Collaboration with sports physicians on risk, treatment, and referral advised.
Global Vision with a Local Flavour
Debates, dry labs, and surgical trainers to highlight 2024 Congress.
Controlling Inflammation after Cataract Surgery
No consensus among leading surgeons regarding whether or how to use a dropless regimen.
Weighing the Cornea Ectasia Risks
Athletes should proceed with care with eye protection solutions.
New Trifocal IOL Delivers Positive Outcomes
Seven diffractive rings offer full range of vision.
Finding a Keratoconus Consensus
Evolving new consensus should help guide diagnosis and management.